Abstract
Sixteen eligible patients with hepatocellular carcinoma, previously untreated, received merbarone 1000 mg/m2/d for five consecutive days every 21 days. No complete or partial response to treatment was obtained. Seven patients had grade 4 granulocytopenia. One patient died with renal failure. Merbarone in this dose and schedule was ineffective in the treatment of hepatocellular carcinoma.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Carcinoma, Hepatocellular / drug therapy*
-
Female
-
Humans
-
Liver Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Thiobarbiturates / adverse effects
-
Thiobarbiturates / therapeutic use*
Substances
-
Antineoplastic Agents
-
Thiobarbiturates
-
merbarone